Clinical trial · Interventional
Treatment Strategy for Low-grade Gliomas
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Difficulty in recruiting patients
Summary
Brief summary (as posted)
Although the prognosis of patients with low-grade glioma (LGG) is generally good, recurrence seems unavoidable in some patients because of the infiltrative growth of the tumors. How to treat LGGs is still under controversy. The role of radiation therapy and chemotherapy in the treatment of LGG need to be further investigated. The purpose of this study is the following: 1. to investigate the role of early radiation therapy in MRI-determined total resected LGGs; 2. to compare the efficacy of early radiation therapy and that of initial chemotherapy in the LGGs without total resection.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Astrocytomas | Astrocytic Tumor | ALIAS | 0.90 |
| Oligoastrocytoma | Oligoastrocytoma | CURATED_BROADER | 0.80 |
| Oligodendrogliomas | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radiation therapy | Radiation | — | UNRESOLVED |
| Temozolomide | Drug | Temozolomide | ALIAS |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Total resection with early radiation
- description
- Total resected LGGs treated with early radiation
- interventionNames
- Radiation: Radiation therapy
- type
- NO_INTERVENTION
- label
- Total resection without radiation
- description
- Total resected LGGs treated without radiation
- type
- EXPERIMENTAL
- label
- Residual LGGs with radiation
- description
- Residual LGGs treated with early radiation
- interventionNames
- Radiation: Radiation therapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed newly diagnosed low-grade gliomas * Karnofsky performance status of 60 or more Exclusion Criteria: * Previous history of radiation therapy or chemotherapy for gliomas * Pregnant or breast feeding * Diagnosis of another malignancy may exclude subject from study * Evidence or history of bleeding diathesis * Evidence or history of hypersensitivity to temozolomide
References
Publications (0)
Data not yet available